[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Central Lancashire\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":184},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,62,83,104,126,144,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100634608","effects-of-berberine-on-cardiometabolic-outcomes-100634608",false,"NCT07541898","Effects of Berberine on Cardiometabolic Outcomes","Effects of Berberine Supplementation on Cardiometabolic Parameters","Inclusion Criteria:\n\n* Healthy\n* Between 18 \\& 65 years\n* Non-smoker\n* BMI \\\u003C 30\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Diabetes or any other metabolic\u002F uncontrolled hypertensive conditions\n* Food allergies to berberine\n* Habitual consumption of berberine\n* Not regularly taking medication or antioxidant supplements",true,"ALL","18 Years","65 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Berberine may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.",[28],"Cardiometabolic Syndrome","NOT_YET_RECRUITING","2026-04-14",{"date":32,"type":33},"2026-04-21","ACTUAL",{"date":35,"type":22},"2026-07-01",{"date":37,"type":22},"2029-01-01",{"name":39,"class":40},"University of Central Lancashire","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100533825","effects-of-quercetin-on-cardiometabolic-outcomes-100533825","NCT06230861","Effects of Quercetin on Cardiometabolic Outcomes","Effects of Quercetin Supplementation on Cardiometabolic Parameters","Inclusion Criteria:\n\n* Healthy\n* Between 18 \\& 65 years\n* Non-smoker\n* BMI \\\u003C 30\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Diabetes or any other metabolic\u002F uncontrolled hypertensive conditions\n* Food allergies to quercetin\n* Habitual consumption of quercetin\n* Not regularly taking medication or antioxidant supplements",{"count":21,"type":22},[25],"Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.",[28],"RECRUITING","2026-02-25",{"date":55,"type":33},"2026-02-27",{"date":57,"type":33},"2024-03-01",{"date":59,"type":22},"2026-12-01",{"name":39,"class":40},1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100619888","effects-of-vibration-assisted-physical-activity-in-type-2-diabetes-100619888","NCT07350473","Effects of Vibration-Assisted Physical Activity in Type-2 Diabetes","Vibration-Assisted Physical Activity for Glycaemic Control in Type-2 Diabetes: A Randomised Controlled Trial in the Kingdom of Saudi Arabia","VIBRANT-KSA","Inclusion Criteria:\n\n* Clinically established diagnosis of type-2 diabetes for at least 12 months\n* Previously sedentary\n* Knowledgeable about hypoglycaemia\n* Aged over 18 years\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\n* Cognitive impairment precluding consent or participation\n* Pregnancy\n* Additional medical conditions that prevent safe physical activity (e.g. severe arthritis or advanced heart failure)\n* Enrolment in any other clinical trial designed to influence type-2 diabetes symptoms.",{"count":71,"type":22},305,[25],"The World Health Organization ranks Saudi Arabia as having the 7th highest rate of type-2 diabetes in the world. This therefore makes diabetes the most challenging health problem facing Saudi Arabia. Importantly, physical activity has been shown to improve disease symptoms and overall health in patients with type-2 diabetes. However, findings relating to the prevalence of physical inactivity in the Saudi population confirm that a sedentary lifestyle is on the rise, within physical inactivity levels in adults being 80.5%. Therefore, interventions aimed at reducing physical inactivity using bespoke modalities pertinent to Saudi Arabia are clearly warranted.\n\nThere have been no fully powered, placebo-controlled trials of localised wearable calf vibration in T2DM within the Kingdom of Saudi Arabia. The proposed study will address this gap by evaluating a 12 week, home based, seated calf vibration intervention in Saudi adults with T2DM, recruited from the Jazan Diabetes and Endocrinology Center. A three-arm design will compare active localised vibration, a sham vibration condition and usual care.",[75],"Diabetes Mellitus, Type 2","2026-02-19",{"date":78,"type":33},"2026-02-23",{"date":59,"type":22},{"date":81,"type":22},"2029-12-01",{"name":39,"class":40},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":61},"100615704","can-acute-photobiomodulation-improve-balance-and-cognition-in-individuals-with-ataxia-a-pilot-feasibility-placebo-randomized-controlled-trial-100615704","NCT07296068","Can Acute Photobiomodulation Improve Balance and Cognition in Individuals With Ataxia: a Pilot Feasibility Placebo Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age 18-70 years (inclusive)\n* Diagnosis of ataxia\n* Able to walk independently for at least 5 minutes, with or without an assistive device\n* Able to stand safely for balance testing, with or without an assistive device\n* Hemodynamically stable (stable blood pressure and heart rate at rest)\n* On a stable medication regimen for ≥4 weeks prior to enrolment\n* Sufficient vision and hearing (with usual aids if required) to complete balance and cognitive assessments\n* Able to complete study questionnaires and cognitive tasks (with assistance for reading\u002Fwriting if required)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Current or past history of head injury\n* Use of medications acting on the central nervous system\n* Active skin conditions on the forehead or scalp\n* Any other major neurological disorder that could independently affect balance or cognition\n* Ongoing brain stimulation therapy\n* History of migraines\n* Sensitive skin, allergies","70 Years",{"count":91,"type":22},20,[25],"Cerebellar ataxias cause progressive impairments in balance, gait coordination, motor timing, and cognitive functions such as attention and executive control (Buckner, 2013; Salmi et al., 2010; Timmann \\& Daum, 2007). These symptoms substantially reduce independence and quality of life, and current treatments remain limited. There is an urgent need for safe, low-burden interventions that can support everyday functioning and potentially enhance compensatory neural processes.\n\nTranscranial photobiomodulation (tPBM) uses red and near-infrared light (600-1100 nm) to modulate mitochondrial cytochrome-c oxidase, increasing ATP production, reducing oxidative stress, and improving cerebral blood flow (Hamblin, 2016; Salehpour et al., 2019). Several studies show that tPBM can acutely improve cognitive performance and motor control in both healthy adults and clinical groups (Barrett \\& Gonzalez-Lima, 2013; Chan et al., 2019; Henderson \\& Morries, 2017). A growing neurobiological literature suggests that light can penetrate posterior cortical areas sufficiently to modulate networks involving cerebellar-cortical loops (Jagdeo et al., 2012).\n\nImportantly for ataxia, preliminary work shows that tPBM may acutely improve balance stability and gait metrics in older adults and patients with neurological conditions (Moro et al., 2022; Shin et al., 2021). In our own laboratory, we have observed immediate improvements in sway range and cognitive control in older adults after a 24-minute tPBM session applied over midline and posterior scalp regions. These medium to large size effects are consistent with enhanced sensorimotor integration and improved control of attention in distracting environments.\n\nGiven that individuals with cerebellar ataxia experience both motor incoordination and difficulties in maintaining cognitive stability under distracting conditions, tPBM is a promising non-pharmacological intervention worth preliminary investigation.",[95],"Ataxia","2025-12-08",{"date":98,"type":33},"2025-12-22",{"date":100,"type":22},"2026-06-01",{"date":102,"type":22},"2027-12-10",{"name":39,"class":40},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":16,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":61},"100613001","can-photobiomodulation-improve-balance-and-cognition-in-individuals-over-60-a-pilot-feasibility-placebo-randomized-controlled-trial-100613001","NCT07260903","Can Photobiomodulation Improve Balance and Cognition in Individuals Over 60: a Pilot Feasibility Placebo Randomized Controlled Trial.","Inclusion Criteria:\n\n* Aged from 60-80 years\n* Ability to complete written questionnaires independently\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Current or past history of head injury\n* Use of medications acting on the central nervous system\n* Active skin conditions on the forehead or scalp\n* Ongoing brain stimulation therapy\n* History of migraines\n* Sensitive skin, allergies","60 Years","80 Years",{"count":113,"type":22},60,[25],"As people age, changes in balance and memory can make daily life more difficult and increase the risk of falls. Falls are one of the main causes of injury, hospitalization and loss of independence in older adults, while even mild declines in memory and concentration can reduce confidence, social participation and overall quality of life. Therefore, safe, affordable, and practical ways to help older adults remain steady on their feet and mentally sharp are urgently needed.\n\nThe aim of this project is therefore to conduct a pilot feasibility randomized controlled trial to examine whether regular home-based photobiomodulation can improve balance and cognitive function in adults aged over 60. If successful, this research could help shape future strategies for preventing falls, enhancing wellbeing and maintaining independence in older people.",[117],"Age >60","2025-11-21",{"date":120,"type":33},"2025-12-03",{"date":122,"type":33},"2025-06-01",{"date":124,"type":22},"2027-07-10",{"name":39,"class":40},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":61},"100577218","effects-of-green-tea-on-cardiometabolic-outcomes-100577218","NCT06795438","Effects of Green Tea on Cardiometabolic Outcomes","Effects of Green Tea Supplementation on Cardiometabolic Parameters",{"count":21,"type":22},[25],"Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Green tea may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.",[28],"2025-03-24",{"date":138,"type":33},"2025-03-27",{"date":140,"type":22},"2025-04-01",{"date":142,"type":22},"2027-06-01",{"name":39,"class":40},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":4},"100585409","health-benefits-of-tart-cherry-in-crohns-disease-100585409","NCT06901986","Health Benefits of Tart Cherry in Crohn's Disease","Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Crohn's Disease.","Inclusion Criteria:\n\n* An established diagnosis of CDfor at least 6 months\n* Current mild to moderate disease activity\n* Age between 18 and 65 years\n* Stable use of medication for at least 3 months respectively.\n\nExclusion Criteria:\n\n* Diabetes\n* HIV\n* Hepatitis B and C infection\n* Abscesses\n* Unstable medical conditions that would likely prevent the subject from completing the study\n* Food allergies to cherries.",{"count":152,"type":22},52,[25],"Crohn's disease (CD) is a long-term inflammatory condition of the digestive tract. People with CD often experience unpredictable and debilitating symptoms, including abdominal pain, diarrhea, and fatigue. Additionally, they require long-term treatment, which is often associated with frequent negative effects, the need for surgery, and hospitalizations. As a result, individuals with CD report a lower health-related quality of life (HRQOL) compared to healthy individuals.\n\nThe most common medication for inflammatory bowel disease is a strong immunosuppressant, which was identified in 2017 as the most expensive medication prescribed in NHS hospitals. Unfortunately, biologics have significant side effects, and reducing the reliance on them could benefit both the NHS by lowering costs and patients by minimizing unwanted side effects.\n\nSupplementation with Montmorency tart cherry juice may offer a simple, safe, and cost-effective intervention for improving symptoms in individuals with CD. This is due to its potential to naturally reduce inflammation in the digestive system, thereby alleviating symptoms. Research in animal models has shown potential improvements in physiological responses with similar supplements, including blueberries, black raspberries, and Montmorency tart cherries, though only one study in human participants has explored bilberry supplementation.\n\nDespite Montmorency tart cherries having superior anthocyanin concentrations compared to other berries, dietary interventions using tart cherry supplementation for CD have not been explored in human participants. The primary aim of the proposed investigation is to conduct a placebo-controlled randomized trial to examine whether Montmorency tart cherry juice supplementation can provide symptom relief and improve health-related well-being in individuals with mild to moderately active CD, as well as to understand the biological mechanisms underlying any observed symptom changes.",[156],"Crohn Disease (CD)","2025-03-23",{"date":159,"type":33},"2025-03-30",{"date":161,"type":22},"2026-01-01",{"date":142,"type":22},{"name":39,"class":40},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":183,"locationsCount":61},"100559119","effects-of-a-brown-seaweed-tart-cherry-blend-in-mild-moderate-hypertension-100559119","NCT06559982","Effects of a Brown Seaweed Tart Cherry Blend in Mild-moderate Hypertension","Effects of a Brown Seaweed Extract and Tart Cherry Blend Cardiometabolic Outcomes in Participants With Mild-moderate Hypertension an Ex-vivo Optimized Pilot Feasibility Trial","Inclusion Criteria:\n\n* Aged from 18-65 years\n* Systolic blood pressure 120 to 139 mmHg\n* Not taking prescribed medicine for blood pressure management\n* Ability to complete written questionnaires independently\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed with diabetes mellitus and\u002F or coronary heart disease\n* Pregnant and lactating women\n* Allergy to peppermint\n* Habitual consumption of peppermint products\n* Regular consumption of antioxidant supplements\n* Body mass index larger than 40.0 kg\u002Fm2\n* Current enrolment in other clinical trials of other external therapies",{"count":172,"type":22},30,[25],"The brown seaweed species Ascophyllum nodosum is rich in bioactive polysaccharides, proteins, peptides, lipids, pigments, and polyphenols. Similarly, Montmorency tart cherry (Prunus cerasus L.) is high in anthocyanins and polyphenols. Both substances have antioxidant, anti-inflammatory, and vasodilatory properties that target mechanisms central to hypertension and cardiometabolic diseases.\n\nDietary interventions to improve cardiovascular health are highly sought after as they possess less risk and financial burden than pharmacological drugs. Previous randomized trial has shown that both brown seaweed and tart cherry supplementation can improving systolic blood pressure and other cardiovascular\u002F blood lipids. However, to date, no research has explored a seaweed - tart cherry blend using a placebo randomized intervention in patients with hypertension.\n\nThe primary purpose of the proposed investigation is to test the ability of a seaweed - tart cherry supplementation blend to improve cardiometabolic parameters in participants with mild-moderate hypertension using a pilot\u002F feasibility study.",[176],"Hypertension","2024-08-18",{"date":179,"type":33},"2024-08-20",{"date":181,"type":22},"2025-05-01",{"date":35,"type":22},{"name":39,"class":40},""]